SPOTLIGHT -
EP. 1: Introduction: FOLFIRINOX in Metastatic Pancreatic Cancer
EP. 2: Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer
EP. 3: Cost Effectiveness of Therapies in Pancreatic Cancer
EP. 4: Optimizing Treatment of Advanced Pancreatic Cancer
EP. 5: Novel Treatment Strategies Explored in Pancreatic Cancer
EP. 6: Emerging Therapies and Novel Targets in Pancreatic Cancer
EP. 7: Case Study: Treatment of Metastatic Pancreatic Cancer
EP. 8: New Drug Development Needed in Pancreatic Cancer
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
